Agilent signed a collaboration agreement with Incyte to leverage Agilent’s expertise in the development of companion diagnostics (CDx) for the development and commercialization of hematology and oncology portfolio
The collaboration integrates both companies to collaborate on CDx development programs. Through the agreement, Agilent expects to expand its companion diagnostic portfolio with novel biomarkers
Moreover, the collaboration gives Incyte the leverage to use Agilent’s expertise in IVD assay development, global regulatory approvals & commercialization to support clinical trials, potential registration & commercialization of CDx in the US & EU
Ref: Agilent | Image: Incyte
Related News:- Incyte Presents Positive 52-Week P-IIb Trial Results of Povorcitinib (INCB54707) for Extensive Nonsegmental Vitiligo at EADV 2023
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
